Latest Updates

    None Found

Boston Children's Hospital research opportunity!

Boston Children’s Hospital recently became a site for a Novartis drug trial testing an mGluR5 antagonist in adults. Additionally, a Novartis trial of the same drug in adolescents is actively recruiting at BCH.

The adult study is for individuals with fragile X ages 18-45, while the adolescent study is for 12-18 year olds. The drug, AFQ056, decreases the activity of mGluR5 in the brain, and the study is looking at whether this has any affect on behavioral symptoms of fragile X. Study participants would be asked to complete 9 study visits over the course of 20 weeks, and would be reimbursed for travel expenses.

Anyone interested can contact Lucy Abernethy, by email at; or by phone: (857) 218-4938, for more information.

More details about either trial can also be found at; the identifier for the adult study is NCT01253629, and for the adolescent study is NCT01357239.

Comments are closed.